CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
出版年份 2016 全文链接
标题
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
作者
关键词
-
出版物
Scientific Reports
Volume 6, Issue 1, Pages -
出版商
Springer Nature
发表日期
2016-01-28
DOI
10.1038/srep20070
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma
- (2015) Jason J. Luke et al. Oncotarget
- Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
- (2014) S. J. Dovedi et al. CANCER RESEARCH
- Generation of Gene-Modified Cynomolgus Monkey via Cas9/RNA-Mediated Gene Targeting in One-Cell Embryos
- (2014) Yuyu Niu et al. CELL
- Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells
- (2014) J J Pen et al. GENE THERAPY
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects
- (2014) Bin Shen et al. NATURE METHODS
- Generating rats with conditional alleles using CRISPR/Cas9
- (2013) Yuanwu Ma et al. CELL RESEARCH
- Generation of gene-modified mice via Cas9/RNA-mediated gene targeting
- (2013) Bin Shen et al. CELL RESEARCH
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Simultaneous generation and germline transmission of multiple gene mutations in rat using CRISPR-Cas systems
- (2013) Wei Li et al. NATURE BIOTECHNOLOGY
- Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
- (2013) Yared Hailemichael et al. NATURE MEDICINE
- Cas9 as a versatile tool for engineering biology
- (2013) Prashant Mali et al. NATURE METHODS
- An Efficient Low Cost Method for Gene Transfer to T Lymphocytes
- (2013) Leonardo Chicaybam et al. PLoS One
- Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells
- (2013) Harjeet Singh et al. PLoS One
- Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
- (2012) Elena Provasi et al. NATURE MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells
- (2012) Maarten Holkers et al. NUCLEIC ACIDS RESEARCH
- A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
- (2012) M. Jinek et al. SCIENCE
- siRNA-mediated silencing of PD-1 ligands enhances tumor-specific human T-cell effector functions
- (2011) K Iwamura et al. GENE THERAPY
- Regulatory T-cell expansion during chronic viral infection is dependent on endogenous retroviral superantigens
- (2011) George A. Punkosdy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells
- (2010) Lisa Borkner et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25Hi regulatory T cells
- (2009) Wenshi Wang et al. INTERNATIONAL IMMUNOLOGY
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search